WHO's Human Genome Editing Standards Must Not Impact Somatic Cell Research
Executive Summary
Concerns have been expressed that efforts by the World Health Organization to establish global standards for the whole spectrum of human genome editing research may inadvertently have a negative impact on companies developing somatic cell therapy medicinal products.
You may also be interested in...
WHO OKs New Genome Editing Registry, Calls For Governance Framework
A new global registry is being set up to log all research involving genome editing, and there are plans for an online consultation on a governance framework on such research. The Alliance for Regenerative Medicine has welcomed the fact that the new registry will not be as burdensome for therapeutic developers as it originally thought.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.